Medexus Pharmaceuticals (FRA:P731) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:P731 Medexus Pharmaceuticals Inc FRA:P731
59 GF Score
Price €3.12
GF Value €1.05
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Medexus Pharmaceuticals FFO per Share?

FFO per Share only applies to REITs.

FRA:P731
59GF Score
Medexus Pharmaceuticals Inc FRA:P731
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Medexus Pharmaceuticals (FRA:P731) Overvalued in 2026?

Based on GuruFocus' analysis, Medexus Pharmaceuticals stock appears to be overvalued. The current stock price of €3.12 is trading 197.1% above its estimated GF Value™ of €1.05. GuruFocus considers Medexus Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:P731:

  • FFO per Share:
  • GF Value™: €1.05 vs. price of €3.12 (197.1% above fair value)
  • GF Score™: 59/100 with 6 warning signs

No single metric tells the full story. See the FRA:P731 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medexus Pharmaceuticals Business Description

Other Exchanges MEDXF:USAMDP:Canada
Address 10 King Street East, Suite 600, Toronto, ON, CAN, M5C 1C3
Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Medexus products are generally sold in North America to wholesalers, distributors, government agencies, healthcare facilities and specialty pharmacies.
59GF Score

Get the complete analysis for FRA:P731

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.12
Price
€1.05
GF Value